CCBIO seminar: Emmet Mc Cormack
Imaging preclinical tumour models: improving translational power
Emmet Mc Cormack
Department of Clinical Science and CCBIO, University of Bergen
The current dogma of rushing novel pharmaceuticals through inappropriate preclinical models is one of the major reasons for the limited clinical penetration of novel drugs. Despite this, the preclinical step in drug development is generally overlooked and models are chosen to fit the desired result, rather than using them as valuable tools to drive clinical development. Here I will present our group’s ongoing work on development, characterisation and application of clinically relevant models (patient-derived xenograft (PDX), humanised patient-derived xenograft (Hu-PDX)) and multimodal molecular imaging strategies (optical including fluorescence image-guided surgery, positron emission tomography/computed tomography (PET/CT), magnetic resonance imaging (MRI), ultrasonography (US)), and how we believe judicious application of these technologies can expedite clinical development of novel therapeutics.
Chairperson: Bjørn Tore Gjertsen, CCBIO